{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Very Good Partial Response (VGPR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Partial Response (PR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Response that was confirmed on 2 consecutive evaluations during treatment.\n\nComplete Response(CR): Complete disappearance of M-protein from serum and urine on immunofixation, normalization of Free Light Chain (FLC) ratio and \\<5% plasma cells in bone marrow.\n\nVery Good Partial Response(VGPR): \\>=90% reduction in serum M-component; Urine M-Component \\<=100 mg per 24 hours.\n\nPartial Response(PR): \\>=50% reduction in serum M-component and/or Urine M-Component \\>=90% reduction or \\<200 mg per 24 hours; or \\>=50% decrease in difference between involved and uninvolved FLC levels.","groups":[{"description":"Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.","id":"OG000","title":"Bortez/Cyc/Dex"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Duration of treatment (up to 12 cycles/months)","title":"Number of Participants With a Confirmed Hematologic Response","type":"PRIMARY","unitOfMeasure":"participants"}